Single-arm Study of Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer - Trial NCT06389760
Access comprehensive clinical trial information for NCT06389760 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and is currently Recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Timeline & Enrollment
Phase 2
Oct 18, 2023
Sep 30, 2026
Primary Outcome
disease-free survival (DFS)
Summary
This is a prospective, multicenter, single-arm, phase II trial. The main purpose of the study
 is to evaluate the efficacy and safety of Nimotuzumab combined with mFOLFIRINOX for
 postoperative adjuvant treatment of pancreatic cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06389760
Non-Device Trial